Rating: HOLD
HOLD (5-tier) · mature cash generator · conviction: medium
| Metric | Value |
|---|---|
| Current Price | $76.01 |
| Triangulated Fair Value | $74.85 (-2% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $76.16 (+0% vs spot · 12m PWEV) |
| Forward P/E | 17.0x |
| Market Cap | $11B |
| 52-Week Range | $51.79–$101 |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-07-21. Each chart below sits with the part of the thesis it evidences.
General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.
Investment Committee Summary
| Rating | HOLD · HOLD (5-tier) |
| Classification · conviction | mature cash generator · medium |
| Triangulated fair value | $74.85 (-2% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $76.16 (+0% vs spot · 12m PWEV) |
| Next catalyst | 2026-08-06 — Quarterly earnings |
| Primary thesis-break | Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints) |
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Rating Bridge
Rating = HOLD because:
- Probability-weighted scenario value implies +0% vs spot
- Monte Carlo median implies -10% vs spot
- DCF fair value implies +1% vs spot — but this is terminal-value sensitive (exit-multiple $76.62 vs Gordon $88.30, 15% apart), so it carries less weight
- Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -56% vs spot
- Net: reward/risk of 0.0× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Company Overview & Business Model
Globus Medical — HEALTHCARE · MEDICAL DEVICES. Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
How it makes money.
| Segment | Rev mix | Growth | Op margin | Key driver |
|---|---|---|---|---|
| Medical Devices & Equipment | 100% | +6% | 23% | procedure volumes + product-innovation cycle + hospital capital spendi |
Edge. Wide moat — Wide competitive moat (inferred from a 21% operating margin and 13% ROE and the 'medical_devices' business model). Durable pricing power supports a terminal multiple above the market.
Investment Thesis
[DRAFT — analyst to replace with a first-person thesis] At the current quote Globus Medical is fairly valued vs the engine's triangulated fair value (+0%). The business — Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. — runs an operating margin near 21% on ~13% ROE. The engine's HOLD rests on the 'medical_devices' driver set and the cluster's house view; the bull case is upside re-rating if the demand cycle inflects.
The dashboard below is the whole argument on one page: spot ($76.01) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
[DRAFT — steelman for review] The bear case is a demand downcycle that compresses volumes and the 21% margin simultaneously, with the multiple de-rating as cyclical earnings roll over — the structural scenario in the model. For a mid-cap with thinner coverage, a single guidance cut can re-rate the stock faster than a large-cap peer.
Key Debate
P/E Multiple explains 64% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.39 vs analyst floor +0.01 → delta +0.38 (n=30 mgmt / 28 Q&A; 51th pctile across the S&P book, z -0.1).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.39 | +0.01 | +0.38 |
| 2025Q4 | +0.43 | +0.25 | +0.18 |
| 2025Q3 | +0.46 | +0.35 | +0.11 |
| 2025Q2 | +0.54 | +0.35 | +0.18 |
News (last 365d, 141 articles): avg ticker sentiment +0.16 (bullish 25% / bearish 4%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($33.51) to a 'Bull — Re-Rate' bull case ($135); the probability-weighted blend (PWEV $76.16) is +0% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | 20% | $33.51 | -56% |
| Hospital-Capex / Utilization Recession | 17% | $56.91 | -25% |
| Base — Procedure Volume + Innovation | 35% | $79.04 | +4% |
| Growth — New-Product Cycle / Penetration | 20% | $107 | +40% |
| Bull — Re-Rate | 8% | $135 | +77% |
| Probability-Weighted (PWEV) | — | $76.16 | +0% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $33.51). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 33.51; probability: 0.2.
- Hospital-Capex / Utilization Recession (17%, $56.91). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 56.91; probability: 0.17.
- Base — Procedure Volume + Innovation (35%, $79.04). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 79.04; probability: 0.35.
- Growth — New-Product Cycle / Penetration (20%, $107). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 106.7; probability: 0.2.
- Bull — Re-Rate (8%, $135). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 134.76; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $68.52 | -10% |
| Peer EV/Revenue re-rate | multiple | $61.59 | -19% |
| Scenario PWEV | multiple | $76.16 | +0% |
| DCF (5-year + terminal) | cash flow + terminal × | $76.62 | +1% |
| Triangulated (weighted) | — | $74.85 | -2% |
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $68.52 and 39% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (64% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 14x terminal FCF multiple → $76.62. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 18.905x) implies —. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 0% so the market's mood does not drive the fair value.
Across all anchors the spread is 20% of the median — moderate (healthy method disagreement — read the blend with care).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Medical Devices & Equipment | $3.1B | 100% | 6% | 23% | $0.7B | 17x | 5% | ESTIMATE |
| EBIT = segment revenue × operating margin (segment EBITDA not shown — per-segment D&A is not separately disclosed). |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | procedure volumes + product-innovation cycle + hospital capital spending |
| net_debt_or_cash_b | 0.45 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / competition / GLP-1 procedure hit |
| upside | new-product cycle + penetration |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: ILMN (life_science_tools) · MEDP (life_science_tools) · PEN (medical_devices) · GMED (medical_devices) · BRKR (medical_devices) · BIO (life_science_tools) · AVTR (life_science_tools) · LNTH (medical_devices) · LIVN (medical_devices) · NVST (medical_devices) · DOCS (life_science_tools) · HAE (medical_devices) · XRAY (medical_devices)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $3B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $3B | $1B | $0B | $0B | $1B | $1B |
| FY+3 | $4B | $1B | $0B | $0B | $1B | $1B |
| FY+4 | $4B | $1B | $0B | $0B | $1B | $1B |
| FY+5 | $4B | $1B | $0B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 14x | $7B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $3B + PV(terminal) $7B = EV $10B; + net cash $0.5B → equity $11B ÷ diluted shares 0.14B = $76.62/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $88.30/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 18% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| BRKR | 3.007x | 15.22x | 6% | 6% |
| LIVN | 2.957x | 19.08x | 6% | 14% |
| ENSG | 2.211x | 22.68x | 4% | 9% |
| EHC | 2.276x | 18.73x | 4% | 19% |
| Median | 2.6165x | 18.905x | — | — |
Peer-median fwd P/E → —; EV/Rev → $61.59.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $76.62 | 47% | $35.76 |
| Scenario PWEV | $76.16 | 33% | $25.39 |
| Monte Carlo median | $68.52 | 20% | $13.70 |
| Triangulated | — | 100% | $74.85 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| 6% | $65.00 | $74.00 | $83.00 | $92.00 | $100 |
| 8% | $63.00 | $71.00 | $80.00 | $88.00 | $96.00 |
| 8% | $61.00 | $69.00 | $77.00 | $85.00 | $93.00 |
| 10% | $59.00 | $66.00 | $74.00 | $81.00 | $89.00 |
| 10% | $56.00 | $64.00 | $71.00 | $78.00 | $85.00 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $61.00 | $65.00 | $69.00 | $73.00 | $77.00 |
| -1.5pp | $64.00 | $68.00 | $73.00 | $77.00 | $81.00 |
| +0.0pp | $67.00 | $72.00 | $77.00 | $81.00 | $86.00 |
| +1.5pp | $71.00 | $76.00 | $81.00 | $86.00 | $91.00 |
| +3.0pp | $75.00 | $80.00 | $85.00 | $91.00 | $96.00 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $67.00 | $86.00 | $18.00 |
| Revenue CAGR ±3pp | $69.00 | $85.00 | $17.00 |
| Terminal × ±15% | $69.00 | $85.00 | $16.00 |
| WACC ±1pp | $74.00 | $80.00 | $6.00 |
| Capex intensity ±15% | $74.00 | $79.00 | $5.00 |
Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 17x)
| Multiple | 11.9x | 14.4x | 17.0x | 19.5x | 22.1x |
|---|---|---|---|---|---|
| SoP/share | $64.00 | $77.00 | $90.00 | $103 | $116 |
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $106 (+39% vs spot · street) |
| House target | $76.16 (-28.0% vs street) |
| Sell-side coverage | 13 analysts (SB 3 / B 6 / H 4 / S 0 / SS 0; net score 0.46) |
| Consensus FY EPS | $5.15; house below (-13.0%) |
| Consensus FY revenue | $3.4B; house below (-3.1%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $-0.4B — net cash |
| Net debt / EBITDA | -0.46x |
| Current ratio | 4.27x |
| Lease obligations | $0.1B |
| Cash & ST investments | $0.6B |
Balance-sheet data as of 2025-12-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $0.6B |
| Buybacks / dividends | $0.3B / $0.0B |
| Total shareholder yield | 2.8% |
| Payout as % of FCF | 50.9% |
| Reinvestment (capex / OCF) | 21.9% |
| SBC as % of FCF | 8.5% |
| Allocation stance | balanced |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 19.0% |
| FCF conversion (FCF / net income) | 109.5% |
| FCF yield | 5.6% |
| Capex intensity (capex / revenue) | 5.3% |
| FCF − SBC (diagnostic) | $0.5B |
Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 140% — cash-backed.
Catalyst Calendar
- 2026-08-06 (~16d) — Quarterly earnings — est. EPS $1.12 (AV EARNINGS_CALENDAR)
- 2026-08-06 (~16d) — Quarterly earnings (AV EARNINGS_CALENDAR)
Forecast Track Record
- EPS surprise: beat 87.5% of the last 8 quarters; average surprise +17.2%.
Competitive Moat
Wide moat. Wide competitive moat (inferred from a 21% operating margin and 13% ROE and the 'medical_devices' business model). Durable pricing power supports a terminal multiple above the market.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | Cluster state 'Reimbursement / Funding / Utilization Reset' (house prob ~37%) | Path-dependency: a single disappointing print can shift the book toward the adjacent-bear state. |
| Hospital-Capex / Utilization Recession | Cluster state 'Reimbursement / Funding / Utilization Reset' (house prob ~37%) | Path-dependency: a single disappointing print can shift the book toward the adjacent-bear state. |
| Base — Procedure Volume + Innovation | Cluster state 'Mid-Cycle — Procedure & R&D Demand' (house prob ~35%) | Path-dependency: a single disappointing print can shift the book toward the adjacent-bear state. |
| Growth — New-Product Cycle / Penetration | Cluster state 'Mid-Cycle — Procedure & R&D Demand' (house prob ~35%) | Path-dependency: a single disappointing print can shift the book toward the adjacent-bear state. |
| Bull — Re-Rate | Cluster state 'Upside — Innovation / Recovery Re-Rate' (house prob ~28%) | Path-dependency: a single disappointing print can shift the book toward the adjacent-bear state. |
What the Market Is Pricing In
At the current price, the market pays 14.8× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 18.905×. The house DCF sits 1% above spot, so the market is pricing in less than the house case — roughly 0.1pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 3.4 | 3.3 | High |
| EPS | 5.2 | 4.5 | Medium |
| Target price | 105.8 | 76.2 | Medium |
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| BRKR | 15.22× | 6% | 6% | direct | 100% |
| LIVN | 19.08× | 6% | 14% | direct | 100% |
| ENSG | 22.68× | 4% | 9% | segment | 50% |
| EHC | 18.73× | 4% | 19% | direct | 100% |
Quality-weighted forward P/E: 18.4× (simple median 18.905×). Direct peers count 100%, segment 50%, broad 25%.
Historical-range cross-check: 52-week range $51.79–$101, centre $72.50 (-5% vs spot); spot sits at the 49th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV | $74.85 (-2% vs spot · triangulated FV) |
| Downside to bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) | $33.51 (-56% vs spot · bear scenario) |
| Reward/risk ratio | 0.0× |
| Margin of safety (FV vs spot) | -2% |
| P(price > spot) — Monte Carlo | 39% |
Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $135.
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 8.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 14× | DCF exit value | estimate (peer-anchored) |
| Terminal growth | 2.5% | DCF Gordon terminal | estimate |
| SBC dilution | 0.0%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (18.0); Revenue CAGR ±3pp (17.0); Terminal × ±15% (16.0); WACC ±1pp (6.0); Capex intensity ±15% (5.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $3.1B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $3.3B | company guidance | Company guidance | Medium | Forecast, SoP |
| Consensus FY EPS | $5.15 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.139B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $-0.438B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 8.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 14× | house estimate | Peer/historical range | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | DCF Gordon terminal |
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-07-21 | Price, market cap, EV, 52-week range, forward P/E | Alpha Vantage 2026-07-21 |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-21 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-21 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-21 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-07-21 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-07-21 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-07-21 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-07-21 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-07-21 | Segment revenue, margins, multiples, AI decomposition | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-07-21 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-07-21 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 11/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $4B. Triangulation leans 47% on DCF, 33% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints → health_devices_tools). Sustained demand rollover breaks the base case toward the recession scenario.
Fact / Inference / Speculation
- FACT: Spot $76.01; 52-week range $51.79–$101; engine rating HOLD; house target $76.16 (+0%). (source: Alpha Vantage 2026-07-21, 21 July 2026)
- INFERENCE: Triangulated FV $74.85 (-2% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Recommendation: HOLD
Balanced: triangulated fair value $74.85 (-2% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Options Overlay
A defined-risk way to express the HOLD equity view. Chain as of 2026-07-20 (last close) — indicative, not executable quotes.
Market signals — ATM IV 48.3% (moderate regime) · expected move ±11.4% (2026-08-21) · put/call OI 0.47 · ATM Δ 0.574 / Θ -0.07 / ν 0.088 · next earnings 2026-08-06. Direction: NEUTRAL (implied return -1.5% to triangulated fair value $74.85).
Covered Call (if held) (Income / neutral) — Short 82 C · 2026-08-21 · premium $2.0 · yield 2.63% · live chain
Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.
Put Spread (income) (Income / would-own) — Short 70 P / Long 65 P · 2026-08-21 · net $0.4 · net entry $69.6 · yield 0.6% · RoR 9% · max loss $4.6 · live chain
Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put. Illustrative — no outcome is implied or guaranteed.
Protective Collar (if held) (Hedge) — Long 68 P / Short 82 C · 2026-12-18 · net $2.62 · floor -11% · cap +9% · live chain
For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling. Illustrative — no outcome is implied or guaranteed.
Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.